Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients
Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing processes are impeding realisation of patient benefits. Ovarian cancer exemplifies the potential value of genetic testing and the shortcomings of current pathways to access testing. Approximately 15%...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Nature Research
2016
|
| _version_ | 1826286953827401728 |
|---|---|
| author | George, A Riddell, D Seal, S Talukdar, S Mahamdallie, S Ruark, E Cloke, V Slade, I Kemp, Z Gore, M Strydom, A Banerjee, S Hanson, H Rahman, N |
| author_facet | George, A Riddell, D Seal, S Talukdar, S Mahamdallie, S Ruark, E Cloke, V Slade, I Kemp, Z Gore, M Strydom, A Banerjee, S Hanson, H Rahman, N |
| author_sort | George, A |
| collection | OXFORD |
| description | Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing processes are impeding realisation of patient benefits. Ovarian cancer exemplifies the potential value of genetic testing and the shortcomings of current pathways to access testing. Approximately 15% of ovarian cancer patients have a germline BRCA1 or BRCA2 mutation which has substantial implications for their personal management and that of their relatives. Unfortunately, in most countries, routine implementation of BRCA testing for ovarian cancer patients has been inconsistent and largely unsuccessful. We developed a rapid, robust, mainstream genetic testing pathway in which testing is undertaken by the trained cancer team with cascade testing to relatives performed by the genetics team. 207 women with ovarian cancer were offered testing through the mainstream pathway. All accepted. 33 (16%) had a BRCA mutation. The result informed management of 79% (121/154) women with active disease. Patient and clinician feedback was very positive. The pathway offers a 4-fold reduction in time and 13-fold reduction in resource requirement compared to the conventional testing pathway. The mainstream genetic testing pathway we present is effective, efficient and patient-centred. It can deliver rapid, robust, large-scale, cost-effective genetic testing of BRCA1 and BRCA2 and may serve as an exemplar for other genes and other diseases. |
| first_indexed | 2024-03-07T01:51:22Z |
| format | Journal article |
| id | oxford-uuid:9a346237-e7c4-4968-a89c-af061036c74d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:51:22Z |
| publishDate | 2016 |
| publisher | Nature Research |
| record_format | dspace |
| spelling | oxford-uuid:9a346237-e7c4-4968-a89c-af061036c74d2022-03-27T00:19:48ZImplementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patientsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:9a346237-e7c4-4968-a89c-af061036c74dEnglishSymplectic ElementsNature Research2016George, ARiddell, DSeal, STalukdar, SMahamdallie, SRuark, ECloke, VSlade, IKemp, ZGore, MStrydom, ABanerjee, SHanson, HRahman, NAdvances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing processes are impeding realisation of patient benefits. Ovarian cancer exemplifies the potential value of genetic testing and the shortcomings of current pathways to access testing. Approximately 15% of ovarian cancer patients have a germline BRCA1 or BRCA2 mutation which has substantial implications for their personal management and that of their relatives. Unfortunately, in most countries, routine implementation of BRCA testing for ovarian cancer patients has been inconsistent and largely unsuccessful. We developed a rapid, robust, mainstream genetic testing pathway in which testing is undertaken by the trained cancer team with cascade testing to relatives performed by the genetics team. 207 women with ovarian cancer were offered testing through the mainstream pathway. All accepted. 33 (16%) had a BRCA mutation. The result informed management of 79% (121/154) women with active disease. Patient and clinician feedback was very positive. The pathway offers a 4-fold reduction in time and 13-fold reduction in resource requirement compared to the conventional testing pathway. The mainstream genetic testing pathway we present is effective, efficient and patient-centred. It can deliver rapid, robust, large-scale, cost-effective genetic testing of BRCA1 and BRCA2 and may serve as an exemplar for other genes and other diseases. |
| spellingShingle | George, A Riddell, D Seal, S Talukdar, S Mahamdallie, S Ruark, E Cloke, V Slade, I Kemp, Z Gore, M Strydom, A Banerjee, S Hanson, H Rahman, N Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients |
| title | Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients |
| title_full | Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients |
| title_fullStr | Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients |
| title_full_unstemmed | Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients |
| title_short | Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients |
| title_sort | implementing rapid robust cost effective patient centred routine genetic testing in ovarian cancer patients |
| work_keys_str_mv | AT georgea implementingrapidrobustcosteffectivepatientcentredroutinegenetictestinginovariancancerpatients AT riddelld implementingrapidrobustcosteffectivepatientcentredroutinegenetictestinginovariancancerpatients AT seals implementingrapidrobustcosteffectivepatientcentredroutinegenetictestinginovariancancerpatients AT talukdars implementingrapidrobustcosteffectivepatientcentredroutinegenetictestinginovariancancerpatients AT mahamdallies implementingrapidrobustcosteffectivepatientcentredroutinegenetictestinginovariancancerpatients AT ruarke implementingrapidrobustcosteffectivepatientcentredroutinegenetictestinginovariancancerpatients AT clokev implementingrapidrobustcosteffectivepatientcentredroutinegenetictestinginovariancancerpatients AT sladei implementingrapidrobustcosteffectivepatientcentredroutinegenetictestinginovariancancerpatients AT kempz implementingrapidrobustcosteffectivepatientcentredroutinegenetictestinginovariancancerpatients AT gorem implementingrapidrobustcosteffectivepatientcentredroutinegenetictestinginovariancancerpatients AT strydoma implementingrapidrobustcosteffectivepatientcentredroutinegenetictestinginovariancancerpatients AT banerjees implementingrapidrobustcosteffectivepatientcentredroutinegenetictestinginovariancancerpatients AT hansonh implementingrapidrobustcosteffectivepatientcentredroutinegenetictestinginovariancancerpatients AT rahmann implementingrapidrobustcosteffectivepatientcentredroutinegenetictestinginovariancancerpatients |